局部抗生素与四肢骨折合并骨折相关感染时抗菌药物耐药风险的关系
该研究为PREP-IT随机试验的二次分析,纳入546例患者的555例骨折相关感染,比较接受与未接受局部抗生素预防者的抗菌药物耐药率。结果显示,在革兰阳性感染中,局部万古霉素组耐药3例(1.7%)vs 未用组2例(0.9%)(p=0.67);在革兰阴性感染中,局部氨基糖苷类组耐药8例(11.6%)vs 未用组10例(6.2%)(p=0.26),均无显著差异。作者结论为未能检测到耐药率差异,提供谨慎的安心但强调需进一步前瞻性分析。
要点
- 在骨折相关感染中,局部万古霉素组万古霉素耐药3例(1.7%)vs 未用组2例(0.9%),p=0.67。
- 局部氨基糖苷类组氨基糖苷类耐药8例(11.6%)vs 未用组10例(6.2%),p=0.26。
- 作者结论为未能检测到耐药率差异,但强调需进一步前瞻性分析。
核心结论
- 在发生骨折相关感染的四肢骨折患者中,分析未能检测到接受与未接受局部抗生素预防策略者之间抗菌药物耐药率的差异。
- 这些发现对局部抗生素的安全性提供谨慎的安心,但强调需进一步前瞻性分析。
研究设计与样本
- PREP-IT(评估骨科创伤术前抗菌皮肤溶液的随机试验项目)研究的二次分析,纳入该试验中所有发生骨折相关感染的患者。
- 共纳入546例患者的555例骨折相关感染,平均年龄50岁,女性39%,白人82%。
- 根据患者在确定性固定术前或术中手术室内是否接受局部抗生素,评估患者人口学、损伤与骨折特征及主要结局(存在抗菌药物耐药性骨折相关感染)。
主要发现
- 268例骨折(264例患者)接受了局部抗生素;接受局部抗生素的患者损伤严重度评分更高,骨折中开放性骨折比例更高。
- 局部抗生素组Gustilo-Anderson IIIB或IIIC型骨折更多,但发生率与无局部抗生素组无显著差异(20% vs 14%;p=0.14)。
- 除年龄较低外,局部抗生素组其他基线及骨折特征与无局部抗生素组相似。
- 革兰阳性感染中,局部万古霉素治疗的骨折中万古霉素耐药3例(1.7%)vs 未用局部万古霉素的骨折中2例(0.9%)(p=0.67)。
- 革兰阴性感染中,接受局部氨基糖苷类的骨折中氨基糖苷类耐药8例(11.6%)vs 未接受局部氨基糖苷类的骨折中10例(6.2%)(p=0.26)。
局限性
- 作者结论指出这些发现对局部抗生素的安全性提供谨慎的安心,但强调需进一步前瞻性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated antimicrobial resistance (AMR) patterns following local antibiotic use in a large cohort of patients with fractures from the PREP-IT (A Program of Randomized Trials to Evaluate Preoperative Antiseptic Skin Solutions in Orthopaedic Trauma) study. We hypothesized that, among patients with extremity fractures who developed fracture-related infection (FRI), there would be no difference in AMR rates between those who had or had not received local antibiotic therapy with surgical fixation. METHODS: This was a secondary analysis of all patients in the PREP-IT trial who developed FRI. Patient demographics, injury and fracture characteristics, and the primary outcome of the presence of an antimicrobial-resistant FRI were evaluated on the basis of whether the patient had or had not received local antibiotics in the operating room prior to, or at, definitive fixation. RESULTS: A total of 555 FRIs in 546 patients (mean age, 50 years; 39% female; and 82% White) were included. A total of 268 fractures (264 patients) received local antibiotics. The Injury Severity Score and the proportion of open fractures were higher among patients and fractures that received local antibiotics, respectively. There were more Gustilo-Anderson type-IIIB or IIIC fractures in the local antibiotic group, but the rate did not differ significantly from that in the group with no local antibiotics (20% versus 14%; p = 0.14). Other baseline and fracture characteristics were similar between the groups, with the exception of age (lower in the group with local antibiotics). When examining FRIs with gram-positive organisms, we found that 3 (1.7%) of the FRIs in fractures that had been treated with local vancomycin had organisms resistant to vancomycin compared with 2 (0.9%) of the FRIs in fractures for which local vancomycin had not been used (p = 0.67). When examining FRIs with gram-negative organisms, the number of FRIs with aminoglycoside-resistant organisms was 8 (11.6%) among fractures that received local aminoglycosides and 10 (6.2%) among fractures that did not receive local aminoglycosides (p = 0.26). CONCLUSIONS: Among extremity fractures that developed FRI, we were unable to detect differences in the rates of AMR between fractures treated with or without local antibiotic prophylactic strategies in our analysis of a randomized trial of various skin preparation solutions for extremity trauma surgery. These findings provide cautious reassurance regarding the safety of local antibiotics but underscore the need for further prospective analysis. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Schrank GM, Jozefowski N, Zura RD, et al. Local Antibiotics and the Risk of Antimicrobial Resistance in Extremity Fractures Complicated by Fracture-Related Infection. J Bone Joint Surg Am. 2025. PMID: 40531179. doi:10.2106/JBJS.24.01178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。